Chemed (CHE) Cost of Revenue (2009 - 2026)

Chemed has reported Cost of Revenue for 18 years, with the latest figure at $441.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 2.61% year-over-year to $441.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 5.9% YoY), and the FY2025 full-year result was $1.7 billion, up 8.23% from the prior year.
• Cost of Revenue for Q1 2026 stood at $441.7 million, up from $414.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $441.7 million in Q1 2026, with the low at $336.6 million in Q1 2022.
• Average Cost of Revenue over 5 years is $385.9 million, with a median of $385.1 million recorded in 2024.
• Year-over-year, Cost of Revenue decreased 3.9% in 2022 and gained 13.26% in 2024.
• Tracing CHE's Cost of Revenue over 5 years: stood at $349.6 million in 2022, then increased by 2.51% to $358.3 million in 2023, then grew by 13.26% to $405.9 million in 2024, then climbed by 2.04% to $414.2 million in 2025, then gained by 6.66% to $441.7 million in 2026.
• The last three Cost of Revenue figures came in at $441.7 million (Q1 2026), $414.2 million (Q4 2025), and $428.0 million (Q3 2025), per Business Quant data.

Peer Comparison